tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Can-Fite announces 9-year survival with complete cure with Namodenoson
PremiumThe FlyCan-Fite announces 9-year survival with complete cure with Namodenoson
2M ago
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
Premium
Ratings
Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
2M ago
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
Premium
The Fly
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
2M ago
Can-Fite BioPharma trading halted, news pending
PremiumThe FlyCan-Fite BioPharma trading halted, news pending
6M ago
Can-Fite BioPharma announces group from UCLA demonstrate Piclidenoson efficacy
Premium
The Fly
Can-Fite BioPharma announces group from UCLA demonstrate Piclidenoson efficacy
6M ago
Can-Fite BioPharma files to sell 4.9M American depositary shares
Premium
The Fly
Can-Fite BioPharma files to sell 4.9M American depositary shares
6M ago
Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
PremiumThe FlyCan-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
9M ago
Can-Fite BioPharma trading resumes
Premium
The Fly
Can-Fite BioPharma trading resumes
9M ago
Can-Fite BioPharma announces $3.0M registered direct offering of ADSs
Premium
The Fly
Can-Fite BioPharma announces $3.0M registered direct offering of ADSs
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100